Roadmaps for Progress
The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson’s today.
Dear Friend,

One of the great gifts of my life is that I’ve been in a position to take my experience with Parkinson’s and combine it with the perspectives and expertise of others to accelerate improved treatments and a cure.

In 2017, thanks to your generosity and fierce belief in our shared mission, we moved closer to this goal than ever before.

For helping us put breakthroughs within reach — thank you.

With gratitude,

A Note from Michael J. Fox

“What matters most isn’t getting diagnosed with Parkinson’s, it’s what you do next. The choices we make after we’re diagnosed can open doors to possibilities you’d never imagine.”

—David Iverson, Patient Council

Co-Chair 2016-2018
Dear Friend,

Understanding Parkinson’s disease is the starting point of every effort to accelerate the cure. Years of work spent uncovering Parkinson’s secrets — defining the highly variable patient experience, shedding light on genetic origins of disease, mapping molecular pathways — are now paying off in a tangibly quickening tempo of progress. Researchers are increasingly linking pathology to clinical symptoms (and vice versa) to inform therapeutic target and biomarker identification.

This has positioned drug makers to make rapid inroads toward treatments with potential to slow, stop and perhaps even prevent Parkinson’s disease (PD) symptoms and cell loss. 2017 saw the launch of the first precision medicine clinical trials targeting genetically defined forms of Parkinson’s disease (LRRK2 and GBA). Numerous therapies acting on other pathologies, or auguring improved management of disabling symptoms, continued through clinical trials, pushing ever closer to market. Multiple consortia and countless investigators worked in tandem to fill in ever-larger sections of the Parkinson’s puzzle, characterizing cellular pathways and linking outward dysfunction to underlying disease progression. A cornerstone of these efforts, our Parkinson’s Progression Markers Initiative (PPMI), is influencing clinical trial design and vastly improving understanding of the natural history of disease. Today, researchers are maximizing the value of precious PPMI samples through cutting-edge “omics” analyses, techniques that are speeding the identification of novel biomarker candidates and the nomination of improved therapeutic targets.

And, as demonstrated in part by the willingness of patients and families to participate in PPMI, The Michael J. Fox Foundation (MJFF) also has invested in building more onramps for engaging the PD community. In October 2017, we launched Fox Insight (foxinsight.org) — our online clinical study that is gathering patient-reported data on experience of PD from, at time of printing, nearly 20,000 people with PD and their loved ones. The study aims to enroll hundreds of thousands of people amplifying the patient voice in Parkinson’s research. In collaboration with 23andMe, Fox Insight is also capturing genetic data for continued biological discovery, matching genotype to phenotype.

While 2017 was a year full of progress and promise in Parkinson’s research, much work remains to reveal the molecular fingerprint of the disease, draw lines between pathological bad actors and physical manifestation, and transform rapidly accumulating insights into reliable measures and curative therapies. This information is critical to speed development of therapeutics already under way as well as those still to be discovered. On the following pages, we share the Foundation’s roadmap approach, designed to enable and structure this work in order to accelerate knowledge turns.

We couldn’t do it without you. Your support is helping usher in a future without Parkinson’s disease. Thank you.

With gratitude,

Todd Sherer
Chief Executive Officer

Debi Brooks
Co-Founder and Executive Vice Chairman

2017 Progress in Drug Development

The Parkinson’s drug development pipeline is abuzz with activity, and new therapies to treat motor and non-motor symptoms are market-bound.

Two new Parkinson’s drugs hit pharmacy shelves in 2017. Newron’s Safinamide (Xadago), an add-on therapy for those dealing with persistent symptoms despite levodopa, received U.S. Food and Drug Administration (FDA) approval in March. And the first drug specifically indicated for levodopa-induced dyskinesia — Adamas’ Gocovri, an extended-release formulation of amantadine — arrived in August. MJFF enabled the drug on its path by providing strategic leadership and $1 million in funding for the development of a rating scale instrumental to testing dyskinesia drugs in clinical trials (and thus attracting industry investment in therapeutic development in this area). Adamas also was the first to recruit trial participants through Fox Trial Finder (foxtrialfinder.org), our innovative smart-match tool designed to increase the flow of ready volunteers into the Parkinson’s clinical trials that urgently need them. Including these new therapies, seven Parkinson’s drugs have been approved in the past three years.

At time of publication of this report, two more MJFF-funded experimental drugs for Parkinson’s drugs have been approved in the past three years.

The Parkinson’s drug development pipeline is abuzz with activity, and new therapies to treat motor and non-motor symptoms are market-bound.

Two new Parkinson’s drugs hit pharmacy shelves in 2017. Newron’s Safinamide (Xadago), an add-on therapy for those dealing with persistent symptoms despite levodopa, received U.S. Food and Drug Administration (FDA) approval in March. And the first drug specifically indicated for levodopa-induced dyskinesia — Adamas’ Gocovri, an extended-release formulation of amantadine — arrived in August. MJFF enabled the drug on its path by providing strategic leadership and $1 million in funding for the development of a rating scale instrumental to testing dyskinesia drugs in clinical trials (and thus attracting industry investment in therapeutic development in this area). Adamas also was the first to recruit trial participants through Fox Trial Finder (foxtrialfinder.org), our innovative smart-match tool designed to increase the flow of ready volunteers into the Parkinson’s clinical trials that urgently need them. Including these new therapies, seven Parkinson’s drugs have been approved in the past three years.

At time of publication of this report, two more MJFF-funded experimental drugs for Parkinson’s drugs have been approved in the past three years.
Roadmaps for Progress

Our roadmap approach layers strategic funding and non-financial resources around targets, pathways and symptoms to deepen understanding of Parkinson’s and speed translation.

Cohorts
All therapeutic development begins with the study of the human disease.

MJFF’s extensive constituency comprises more than one million patients, families and supporters — the most active and engaged community in all of Parkinson’s. We leverage this network to assemble and fund cohorts of populations of interest (e.g., those with key genetic mutations, or the newly diagnosed). This work significantly speeds the process of gathering well-characterized data and samples to enable greater understanding of Parkinson’s, new measurement methods and next-generation therapies. The Foundation also is assembling broad cohorts of potential research volunteers mobilized to participate in Parkinson’s studies and trials.

Tools
Freeing researchers from making their own tools leads to better and faster results.

The Foundation pioneered a new model for creating and distributing critical Parkinson’s research tools through direct funding to contract research organizations and field experts. This innovation has freed scientists and drug makers from years and millions of dollars devoted to tool making so they can focus on driving scientific discovery. MJFF also characterizes the best methods and uses for these tools to encourage replicable research. In the clinic, our recruitment tools and online Fox Trial Finder tool help study sponsors enroll volunteers, addressing the systemic problem of slow recruitment.

Biology
Characterization of disease is the backbone of all research progress.

MJFF funds basic and translational science to identify and characterize disease biology, vital to measure Parkinson’s onset/progression or target the disease with new treatments. Exploring cellular functions, defining protein structures, and studying pathological mechanisms in the presence of genetic mutations tee up field-wide advances in therapeutic experimentation and optimization. The Foundation pumps tens of millions of dollars a year into this critical work.

Biomarkers
Objective disease measures speed drug development.

MJFF leads a landmark public-private partnership, among other efforts, to identify and validate candidates for Parkinson’s biomarkers (objective indicators of disease such as blood sugar and diabetes) and develop tests to measure Parkinson’s pathology and symptoms. Toward these goals, researchers are looking at biological factors such as protein levels in addition to phenotypic measures including, for example, eye movement and activity levels (via wearable devices). Objective disease tests would speed drug development by identifying people most likely to respond to treatment, tracking disease progression and assessing therapeutic impact.

Therapies
Transforming early-stage ideas into therapies requires strategy.

The Foundation’s donor-raised capital behaves differently from that of commercial or government research funders in that tangible patient benefit is the only ROI we seek. This frees, indeed obligates, us to seek out and “de-risk” pre-clinical therapeutic studies by helping assemble the data required to attract bigger funders who can advance these projects through more expensive later stages of testing. In addition, MJFF funds trials of repurposed drugs approved for other conditions but that have shown evidence in treating Parkinson’s disease.
2017 in Photos

From top (left to right)

1. Michael J. Fox and Quentin Dastugue (a member of our Patient and Public Policy Councils) with House Majority Whip Steve Scalise (R-LA) and the signed 21st Century Cures Act.
2. Steve Steinthal, Board member Peter Zaffino, Brian Zaffino and Chris McKiernan at Breaking PARkinson’s.
4–6. Regina Lasko and David Letterman; Chairman of the Board Jeff Keesee and Anne Keesee; and Board member David Glickman with Judy Glickman Lauder.
7. In August, key Parkinson’s protein LRRK2 blasted into space for study aboard the International Space Station.
8. Lauren and Seth Rogan at A Funny Thing Happened on the Way to Cure Parkinson’s.
9. CEO Todd Sherer, PhD, and Michael J. Fox join Bill Marks, MD, MS, at Verily Grand Rounds.

From top (left to right)

10. Brad Paisley and Michael J. Fox tip their hats at A Funny Thing Happened on the Way to Cure Parkinson’s.
11. On Giving Tuesday, the Parkinson’s community rallied to raise $1 million in one day for MJFF — with every dollar matched by anonymous donors.
12. Board member and Playing to Win host David Ebbigne.
14. Justin Lepone and Christopher Lloyd go all in with Michael J. Fox and his fellow Board members George Stephanopoulos and Woody Harrelson.
15. Michael J. Fox joins Jane Pauley to discuss the launch of Fox Insight on “CBS Sunday Morning.”
16. Board member Sonny Whelen and Christine Whelen.
2017 Donor Listing

$25 Million and Above
Sergey Brin

$5 Million and Above
The Former Family Foundation

$2.5 Million and Above
Connie and Steven Ballmer
Andy Grove / The Grove Foundation*

$1 Million and Above
Anonymous
Susan and Riley Bechtel
Leslie and Colin Masson
Hartley and Heather Richardson
Christine and Sonny Whelan

The Michael J. Fox Foundation is grateful to the nearly 100,000 donors in 2017 whose generosity pushed our work forward.

This report lists those whose significant contributions helped us fund $98 million in research programs last year.

$400K and Above
Anonymous
The Cure Parkinson’s Trust
The Albert and Judy Glickman Family
Estate of Elfricde Grevendick
Wendy F. Long Charitable Gift Annuity
Jane Comer and Charles Lantz
Robert and Terry Lindsay
Racetrac Petroleum, Inc
Rainwater Charitable Foundation
Great Investors' Best Ideas Foundation / Michele and Sadi Rowe
Signature Bank
Stuart and Suzanne Steele
Estate of Gordon Stevens
Karen Printner and Michael Vlock*

$200K and Above
Anonymous (2)
Estate of Lawrence L. Curtice
The Dickson Foundation*
Estate of Jack L. Fennie
Greenlight Capital, Inc
William and Margaret Fern Holmes
Family Foundation
Rick S. Howell
Estate of Saul Levine
Estate of Louis Lewis
Bar M. Norris Revocable Living Trust
The Pumpkin Foundation / Joe and Carol Bitch
Anne-Cecilie Engell Speyer and Rob Speyer
The Bernard & Anne Spitzer Charitable Trust
Bonnie and Thomas Strauss / The Bachmann-Strauss Dystonia and Parkinson Foundation
Richard Balanson and Dawn Talbot

$100K and Above
Anonymous (3)
Arrell Family Foundation
Revolvoc Trust of Eva Barnes
Alan and Jane Bank
Estate of Mary Bonanno
Lauren and Mark Booth
Marcia and Frank Garuccci
The James E. Gaye and Patricia D. Gaye Charitable Trust
Virginia Clay
Consolidated Anti-Aging Foundation
Diana Darvold
The Demouselle Parkinson Charity
Fairchild-Mattindale Foundation
Estate of Helen Fisher
Lauren and Lee Fixel
Tracy Pollan and Michael J. Fox
The Sam J. Frankino Foundation*
Judie and Howard Ganek
Genuardi Family Foundation
Lisa Piza and David Golub
Golub Capital
The Garley Family Fund
Velma E. Harness Trust
Shannon and Mark L. Hart III
Estate of Helmut P. Herber
Anne and Jeff Krueger
The Lauder Foundation / Leonard and Judy Lauder Fund
The Samuel, Nadia, Sidney and Rachel Leah Fund
Carolyne and Edwin A. Levy
Estate of Rosemary Loughman
The Malkin Family Foundation
Ken Marberen
The Pearl T. Maxon Revocable Trust
Lowell Milken Family Foundation / Sandra Milken
Names Family Foundation
Robin and Andy O’Brien
Julie and Doug O’Toole
Parkinson’s Unity Walk
The Sacks Family Foundation
Carolyn and Curtis Schenker*
Carl S. Schneider
Cathy Seibyl and John Seibyl, MD
Shackleton Family
Nicole Shanahan
Estate of Allan Smidt
Alexandra Weirzworth and George Stephanopoulos
Jack Taylor
Kerry and Chuck Tyler
Dr. Brent and Terry Weinberger Charitable Gift Fund
Marsh and McLennan Companies / Peter Saffino

*Includes payments toward a multi-year gift
To broaden public awareness and recognize key scientific discoveries in dystonia
The Bachmann-Strauss Prize for Excellence in Dystonia Research was established in September 2004 with a leadership commitment from the Bachmann-Strauss Dystonia and Parkinson Foundation (BSDPF), led by MUF Board member Bonnie Strous and her husband, Tom Strauss. The alliance between MUF and BSDPF builds on a working relationship between the foundations that goes back more than a decade.
In 2017, the Foundation honored Andres Lozano, MD, PhD, of the University of Toronto with the Bachmann-Strauss Prize for Excellence in Dystonia Research.

Dystonia is characterized by painful, prolonged muscle contractions that occur when brain cells send out wrong signals. Dr. Lozano’s research was critical to harnessing the power of DBS to correct this dysfunction, dramatically improving quality of life for many living with dystonia.

Inspiring hope for a world free from dystonia
The Robert A. Pritzker Prize for Leadership in Parkinson’s Research was established in 2012 to honor Dr. Michael J. Fox, a catalyst who helped to focus public attention on Parkinson’s disease and whose courage, optimism, and leadership are crucial to the search for cures for Parkinson’s disease and dystonia.

Each fall, The Michael J. Fox Foundation awards two major research prizes to investigators whose groundbreaking studies and leadership are crucial to the search for cures for Parkinson’s disease and dystonia.
Legacy Circle

While MJFF’s mission has always been to find the cure and go out of business, planned gifts provide a major, long-term funding source that we can both plan around, and leverage immediately, to accelerate life-changing research and treatments. Our Legacy Circle honors those who have informed us of their intention to make MJFF a beneficiary of their planned giving.

If you have made estate plans that include The Michael J. Fox Foundation, we would love to know. Please contact Shirley Nagar at snagar@michaeljfox.org.

Judy Mayo and Sid Aaron
Julia Vander May
Bakelaar Charitable Trust
Barbara and Albert Bartko
Sherrie Crotty
John S. Daly
Jane Dilks
Sandra and Mike Ferguson
Cheri and Bill Gibbs
Bernard J. and Joan Herman
Graham K. Jeffrey
Robert Knappman
Steve Kurtz
Wendy F. Lang
Charitable Gift Annuity
Carol and John Lettiere
Sue and Dr. Julian Lifschiz
Kay Livingston
Deborah and Jim Long
Donna Lorrans
Carolyn and Ben Luna
Dorothy MacCulloch
Lisa Morales
Catherine and John Morse
Skip Naler
David Robbins
Janetto Ross
Sarah and Jeffrey Sands
Carl S. Schneider
Dorothy Strauss
Sharron Tune
Deane and Searcy Willis
Bruce Wisnitski

Planned giving — gifts made through retirement accounts, charitable annuities, bequests and estate plans — is a strategy employed by a growing body of MJFF donors to maximize the impact of their philanthropy. For Judy Mayo and Sid Aaron of Georgetown, Texas, naming MJFF as a beneficiary of two IRA retirement funds was a natural next step after supporting MJFF for several years.

The couple now have more than their fair share of experience with Parkinson’s. Several of Judy’s family members have lived with PD; nine years ago, Sid was diagnosed (though he believes he has been living with symptoms for nearly 20 years). As retired toxicologists — scientists trained to study the adverse effects of chemical, physical or biological agents on people, animals and the environment — the couple combined their personal experiences of the disease with their scientific backgrounds, bringing unusual perspective to their decision to support the Foundation.

“We know how much money it takes, the steps that have to be done, and how many drugs don’t make it,” Judy says. “We wanted to support an organization funding research to get treatments to people. And that was MJFF,” says Judy.

Judy and Sid set out to dedicate their legacy to the people and the causes they care about most. They identified five “pillars of importance” representing causes and family members — and sought a giving tool to provide for them all. After speaking to their financial advisor, the IRA emerged as the best choice for their needs.

“We can all play a part in a cure.”

The couple complement their philanthropic giving by working in their local PD community to provide support for other patients and families — something Judy always wished more for her own family.
Industry Partners

Biotechnology and pharmaceutical companies play a key role in the Foundation’s roadmap strategy to accelerate improved treatments for Parkinson’s disease. Their support expands our capability to speed clinical trials, engage the Parkinson’s community in research, and bring science closer to a cure. Collectively, these partners contributed more than $5 million to our programs in 2017.

We also extend our gratitude to the 2017 Parkinson’s Disease Education Consortium. This alliance of industry partners supports our commitment to furnishing high-quality educational resources for the PD community while preserving our track record of efficiency in stewarding donor-raised contributions for maximum impact on Parkinson’s drug development.

Learn more at michaeljfox.org/sponsors.

 Abrivie  
 Accademia Pharmaceuticals*  
 Accorda Therapeutics  
 Adidas Pharmaceuticals*  
 Allergan  
 Amgen  
 Amicus Therapeutics  
 BIO (Biotechnology Innovation Organization)  
 Biogen  
 Bristol Meyers Squibb  
 Cellular Dynamics International*  
 Charles River Laboratories  
 GlimoSmithKline  
 Impax Laboratories  
 Institut de Recherches Internationales Servier  
 Lundbeck*  
 Medical Device Innovation Consortium (MDIC)  
 Merck and Co  
 Meso Scale Diagnostics  
 Pfizer*  
 Prothera Biosciences*  
 Regeneron Pharmaceuticals  
 Sunovion Pharmaceuticals*  
 Takeda Pharmaceuticals International UCB  
 United Technologies Voyager Therapeutics  

$5K and Above (cont.)
Samantha and Justin Snyder  
 Cornelia Daly and Arthur Southam  
 Robert Spaccamore  
 Mary Ann St. Peter  
 Kathleen Stork  
 Lee and Debbie Stuart Family Foundation  
 Cindy and Gary Tiedmeyer  
 William Tore  
 Mary Ann Storberg  
 Ahron and Dorothy H. Steves Foundation  
 Daniel Stevens  
 Peter Stogic  
 Carol and Jim Storzeit  
 Kate Strachan  
 Deborah Strayte  
 Robert and Kollie Summerton  
 Sunny Family Foundation  
 Craig Telman  
 Telefon Foundation  
 Robert L. Tenney  
 Robert Treflar  
 The H.K. Thompson Foundation  
 Ramon and Charles Thompson  
 Alisa and Andrew Tisch  
 Susan and Jay Todd  
 Tidwell Foundation  
 Paul Ulman  
 Patricia and Karl Von Cleve  
 Beth McKittrick and Ben K. Vaughan  
 Alison and Bob Wachstum  
 Iris Walsheen Family Foundation  
 Steve and Susan Weil  
 Estate of Arvon L. Warren  
 Teri Kopp and Walter Weber  
 Linda and George Wilkinson  
 Rita Weinberg Family Trust  
 The John L. & Sue Ann Weinberg Foundation  
 Laurie and Steven Werner  
 George Weiss  
 Sylvia Herbst and Dereck Wolf  
 William J. White  
 Fred and Bath Wilson  
 Donald E. Williams  
 Willis Family Charitable Fund  
 J&J Smith Foundation  
 Floy and Chester Younger  
 Rick and Elaine Yow  
 Anna Wozniak  
 Penny and Daniel Zell  
 Linda Miller and Bruce Wolff  
 Junice and Ann Wolff  
 Rust Yaunke  
 Marion and Anthony Zaffino  
 David Zelko and Family  
 Ruth Zuna  
 Hunter and Andrew Zuckerman  

$2.5K and Above
Anonymous (10)  
 Rob Ask  
 Carol Adams  
 Dale and Paul Adamsbaum  
 The Dr. Anne H. Aldington Charitable Fund  
 Richard Alldredge  
 S.K. Alexander  
 Emily Alfretten  
 Dave Anderson  
 Aggar Black Foundation  
 Michael and Kate Allenberg  
 John Barb  
 Joy and Flaccia Barb  
 Paul Barta  
 Susan and Bruce Barnett  
 Susan and Dale Bartett  
 Arnold and Barbara Barron  
 Velleson Barsh  
 Micky Bass  
 Edward Batchelor  
 Shannon Bauer  
 Mary F. Beck  
 Dr. Holley A. Belch  
 Karen Welsh and James Berbee  
 Don and Carolyn Berge  
 Lee Berger  
 Adar Bergfield  
 Tammy Bergfield  
 Paul Ber  
 Isaac and Sabine Berendt  
 Matthew Berdica  
 Jen Bilik  
 Deed Bilney  
 Susan Blatt  
 Ellen Backman  
 Nancy and Robert S. Blank Foundation  
 Julia Blankshorn  
 Ahti and Michael Blum  
 Douglas A. Rorke  
 Gary and Esther Berenson  
 Jim Brown  
 Sylvia Braddy  
 Rosemary and Michael Brown  
 Jill and Sallie Brownstein  
 Nancy and Greg Brown  
 Dean Brown  
 The Brotherhood Foundation  
 Carly and Martin Brown  
 James Kryas Brown  
 Carliehah Brown  
 Marylynn Brown  
 Eugenia and George Bryan  
 Therese and Joseph Rachner  
 Estate of Irene Louise Caccamino  
 John Caccamino  
 Irene Calho  
 Barbara and Victor Calhoun  
 Kevin and Tina Calhoun  
 Kevin Callahan  
 Louise Canty  
 John Carson  
 Mathew Carpenter  
 Suzanne and David Carroll  
 Ellen Carter  
 Fletcher Carter  
 Mska and Jeff Contreras  
 Mary Combaluzier  
 Robin and Peter Chandler  
 John Cheek  
 Linda Chermont  
 Ernest Chi  
 Vicki Chung  
 Karly and Carl Cilber  
 Dominick Cimino  
 Marissa Cluets  
 Mary Davis and Christian Cocks  
 Matthew Cody  
 Barry Cohen  
 Ray Cole  
 Louise Collins  
 Tracey and Adam Collins  
 Courtney Combs  
 Comins Family  
 John Hofflin and Larry Gordon  
 Barbara and Jim Conen  
 Alfred Combs  
 Eric and Sara Conn Fund  
 Steve Corbin  
 Pam Corinco  
 Christine Conron  
 Adn Craver  
 Laura Daly  
 Peggie Daniel  
 Richard J. Davis, MD  
 Ellen and John Davison  
 Laura and William Davison  
 William Davidson  
 Kathryn A. and Richard Davis  
 Carol and Mac Deacon  
 Gary den Bogden  
 Jerry Denham  
 Aash Desai  
 Jannet and Randall Deltchev  
 Bing Tilton and Cindy Durazo  
 Heather Dole  
 The Dora Family  
 E. Logan Donahue  
 Emilia Deligias-Baptista  
 Mary and Chris Doer  
 Donald Deke  
 Richard Dmitriev  
 Judy Dunn  
 Doyle Foundation, Inc  
 Allison Dooner  
 Lori and Bruce Dubinsky  
 Carol and Dave Dubner  
 Nancy and William Durand  
 Shelley and Michael Egger  
 Dale and Sherry Ehron  
 Rick Eichenman  
 Adam Elen  
 Stuart Ebel and Margy Engil  
 E. Joseph Evans Charitable Trust  
 Victor Evany  
 Vida Everett  
 Kelly and Roger Farber  
 Donald Farnam  
 Amanda and Michael Farned  
 Joanna and Peter Felton  
 The Fenn Family  
 Mari Feinstein  
 Eline Fillion  
 Nicholas Pilli  
 Domenic Fitzgerald  
 Ellen and Lawrence Floyd  
 Neller and John Foster  
 Karen and Greg Fox  
 Ann and Alan Frank  
 Donald Fraser  
 Kipp and Bruce Freeman  
 Timothy Freeman  
 Leslie and Bernard Friedman  
 Anita Fulk  
 Gabriela and Philip Gardner  
 Cara Maggiore and Jay Gannet  
 Ramadan Garbally  
 Jonathan Gottweis  
 Delora Cheryl and Richard Golber  
 Stuart Golberg  
 Joseph George  
 Michael Germerot  
 Matthew Green  
 Amy and Daniel Griswold  
 Mary Gilligan  
 Myrna and Niles Ginsburg  
 Christina Gist  
 Carl Glenn  
 Dan Gluck  
 Renu Gandhi  
 Bruce Glasser  
 Bonnie and Malcolm Goldman  
 Norman and Cecelia Goldschmidt  
 Carolyn Gordon  
 Melissa Gordon  
 Kerry Groves  
 The John B. Gray Charitable Foundation  
 Estate of Lawrence  
 Anthony Greenfield  
 Sharon and Bill Griffin  
 Wycliffe Greenshouse  
 Vincent Guenin  
 Barry Matthew Guthrie, PhD  
 Jason Harris  
 Klemm and Scott Gig  
 Pedro and Michael Hamilton  
 Joanne Hannak  
 Jami and Eshbee Harada  
 Hilary Haron  
 Debra? Herle Harris  
 Bailey Harris  
 Elizabeth and Kenneth Hartung  
 Kathleen Hastings  
 Judy C. Hayward  
 Marcia Hayfield  
 Donna and Michael Haver  
 Bruce Haynam  
 Duncan Healy  
 John and Sarah Holda  
 William Heim  
 David and Chuck Hendricks  
 Renny Pauly  

2017 Annual Report
When Jeffrey Levy of Denver, Colorado, was diagnosed with Parkinson’s in 2014, one of his earliest concerns revolved around what the disease would mean for his love of the outdoors, travel and adventure. He sought out his local Parkinson’s community and soon met new friends living over the disease, “You feel less like empowering and gives you a sense of control,” he says. “You feel less like I was immediately impressed by the work of The Michael J. Fox Foundation. It was thriled to discover the important benefits of participating in the Foundation-led Parkinson’s Progression Markers Initiative (PPMI) and learned Jeff decided to be a contributor to PD. From there, the decision to participate in the Foundation-led PPMI was an obvious one. “If anyone is going to find a cure for this disease, it will be The Michael J. Fox Foundation.”

“Being directly involved in research is empowering and gives you a sense of control over the disease,” he says. “You feel less like a passenger and more like a driver.”

As a lifelong fitness enthusiast, Jeff also was thrilled to discover the important benefits of exercise in managing Parkinson’s symptoms. Alongside volunteering in PPMI, he now regularly participates in events such as “Pedaling 4 Parkinson’s”—an annual Team Fox cycling event in Denver. Jeff shrugs off admiration for his full and active life, “I was immediately impressed by the Foundation’s comprehensive approach to research; they’ve really changed the landscape of Parkinson’s disease.” Jeffrey Levy’s story is a testament to the power of research and the impact it can have on the lives of those affected by Parkinson’s disease.
Corporate Gifts

The Michael J. Fox Foundation is grateful to the following companies for their contributions of nearly $6 million in 2017. Ranging from family-owned small businesses to multinational corporations, these companies support the Foundation’s special events, match employee gifts, organize employee giving campaigns and sponsor community events and grassroots Team Fox fundraisers.

To learn if your employer matches gifts, visit michaeljfox.org/employermatch.
Anne Cohn Donnelly of Winnetka, Illinois, sits at her computer, typing answers into a survey about her Parkinson’s motor symptoms. A 65-year-old retired interior designer, she lives with the disease and the online nature of the study allows her to participate from home. "Being a part of the study is so important to me," she says. "I feel like it’s giving me the strength to face my disease and the activities of daily living. I’m getting stronger," she says. "I decided, ‘I can do this. I can challenge myself.’”

In the fall of 2017, Parkinson’s patients like Anne Cohn Donnelly saw an opportunity to contribute their own unique experiences of living with the disease. The Michael J. Fox Foundation launched Fox Insight, the study was designed to gather data from a large, diverse group of people with Parkinson’s disease and related conditions. Fox Insight is an online clinical study aiming to amplify the Patient Voice in Research. It is designed to provide a more complete picture of Parkinson’s disease variability by engaging thousands of people with Parkinson’s disease from around the world.

Fox Insight is a collaboration between the Michael J. Fox Foundation and 23andMe, a personal genomics and biotechnology company. The study’s goal is to build a large, diverse cohort — providing researchers, drug makers, regulators and patients critical insight into the lived experience, genetics and variability of Parkinson’s disease.

### Milestone Marker: Amplifying the Patient Voice in Research

The Foundation launched Fox Insight (foxinsight.org) in October 2017 in collaboration with personal genetics company 23andMe. The study’s ambitious goal is to build a large, diverse cohort — hundreds of thousands of patients and control volunteers — providing researchers, drug makers, regulators and patients critical insight into the lived experience, genetics and variability of Parkinson’s disease.

### People are hungry for ways to engage.

Increasingly, Parkinson’s patients seek to be active contributors to improved disease understanding and the search for new therapies. “People are hungry for ways to engage,” says Anne, who also is a member of the Foundation's Patient Council. “Now anyone can make a huge difference from the comfort of their home.”

Fox Insight doesn’t replace traditional clinical research, but complements brick-and-mortar studies — which are typically small and extraordinarily expensive — with scale and accessibility, supplementing in-person studies with cohort size and rigorous patient perspective data gathered over time. The study’s flexible design enables integration of diverse data collection modalities — such as remote biological sample collections — and the online nature of the study allows a broader population of patients, who may face geographic, mobility or transportation challenges, to contribute data.

In keeping with the Foundation’s commitment to open-access research, starting later this year, data from Fox Insight will be de-identified and made accessible to qualified Parkinson’s scientists in real time, for independent studies.

Anne is confident that Fox Insight will ultimately contribute to the development of new treatments. But she also finds personal value in using the platform to record and reflect on her journey with the disease. “I see where I’m finding challenges, but also where I’m getting stronger,” she says. “It doesn’t feel like that long ago that Parkinson’s wasn’t going to define me.”
Tributees

The Michael J. Fox Foundation recognizes the following individuals as well as their family members, friends and care partners who gave in their honor or memory in 2017. Celebrate a loved one at michaeljfox.org/tribute.
As people with Parkinson’s disease (PD) and their loved ones know, you can, and should, be your own best advocate. In 2017, The Michael J. Fox Foundation (MJFF) worked with advocates across the country to speak out for public policies that support PD research and care. The Foundation began the year by hosting its first Parkinson’s Policy Forum. More than 200 patients and care partners—including Michael J. Fox—traveled from 43 states to our nation’s capital for two days of advocacy education and training, followed by nearly 200 meetings with members of Congress to highlight the needs of the PD community.

"We are all advocating for a chance to have the best quality of life possible." 

Michael addressed the Forum, saying: “We stand ready to work together to preserve critical federal funds for research and ensure access to health care for everyone living with Parkinson’s.” He led a bipartisan meeting of House leadership to speak about the need for increased research funding. Michael addressed the Forum, saying: “We stand ready to work together to preserve critical federal funds for research and ensure access to health care for everyone living with Parkinson’s.” He led a bipartisan meeting of House leadership to speak about the need for increased research funding.

Advocates went home ready to energize the broader community. “Always remember, your lawmakers work for you. Their offices are open, and they want to hear from you,” says John Humphries of Canton, Georgia. As people with Parkinson’s disease (PD) and their loved ones know, you can, and should, be your own best advocate. In 2017, The Michael J. Fox Foundation (MJFF) worked with advocates across the country to speak out for public policies that support PD research and care. The Foundation began the year by hosting its first Parkinson’s Policy Forum. More than 200 patients and care partners—including Michael J. Fox—traveled from 43 states to our nation’s capital for two days of advocacy education and training, followed by nearly 200 meetings with members of Congress to highlight the needs of the PD community. As people with Parkinson’s disease (PD) and their loved ones know, you can, and should, be your own best advocate. In 2017, The Michael J. Fox Foundation (MJFF) worked with advocates across the country to speak out for public policies that support PD research and care. The Foundation began the year by hosting its first Parkinson’s Policy Forum. More than 200 patients and care partners—including Michael J. Fox—traveled from 43 states to our nation’s capital for two days of advocacy education and training, followed by nearly 200 meetings with members of Congress to highlight the needs of the PD community.
Recurring donations allow many donors to maximize their support of our vital research programs. We are grateful to all who initiated or continued significant recurring gifts to the Foundation in 2017.

Become a monthly donor at michaeljfox.org/monthlygiving.
Rallying friends and family to raise funds for groundbreaking research is a powerful way to help speed a cure for Parkinson’s disease. Last year, 5,800 individuals collectively raised more than $10 million through Team Fox — the Michael J. Fox Foundation’s grassroots, worldwide “passion network” of supporters.

Whether they are pedaling, paddling, Fox Trotting, sipping wine or flipping flapjacks, Team Fox members continue to bowl us over with their far-reaching creativity and determination to eradicate Parkinson’s once and for all.
Team Fox Lifetime MVPs

When Team Fox was launched in 2006, The Michael J. Fox Foundation had a vision of uniting a nationwide network of grassroots fundraisers — patients and families committed to accelerating the cure for Parkinson’s disease. Yet even a group as optimistic as the staff of MJFF could never have envisioned the passion these intrepid individuals would bring. Today, Team Fox is so much more than a fundraising powerhouse, due in no small part to the tremendous accomplishments of those listed below — our lifetime “MVPs.”

While they are listed with their primary events (and board/council affiliations where applicable), these individuals transcend any single channel of involvement. They are active throughout the year as guiding counselors to the Foundation, mentors to fellow Team Fox members and, most of all, supporters of the local and national Parkinson’s community. We are deeply grateful for their seemingly inexhaustible reserves of energy, dedication and generosity.

$3M and Above
Edna Woods, Cindy Theberge, Chris Woods and The Woods Family
New England Parkinson’s Ride, Old Orchard Beach, ME

$2M and Above
Susan Bilotta
Tips for Parkinson’s, New York, NY
Leadership Council
Wendy and Rick Tigner
Tour de Fox Wine Country, Santa Rosa, CA
Board of Directors

$1M and Above
Penny and Quentin Dastugue and The Kickin’ Parkinson’s Committee
A Kickin’ Party, Covington, LA
Patron and Public Policy Councils
Chris and Jim Edlund
D’Elegance, Danville, CA
Karen and Marc Jaffe
Shaking with Laughter, Cleveland, OH
Patron Council
Nicole Jarvis, MD
The Nicole Jarvis MD Winter Gala, Norman, OK
Patron Council
Team VICE
The Creighton Family
NYC Marathon
Board of Directors

2017 Team Fox Donor Listing

$500K and Above
Wendy and Rick Tigner
Tour de Fox Wine Country,
UCSF Celebrity Golf Classic
The Woods Family
New England Parkinson’s Ride

$250K and Above
Nicole Jarvis, MD
The Nicole Jarvis MD Winter Gala
Kickin’ Parkinson’s Committee
A Kickin’ Party, Crozet City Classic 10K
Roy Parker
World Marathon Challenge, Chicago Marathon
Ashley and Justin Vedder
Foxy Gala and Golf Outing, Touchdown for Parkinson’s

$100K and Above
Susan Bilotta
Tips for Parkinson’s – NYC,
NYC Half Marathon, NYC Fox Trot 5K
Walter Florence
Midwest PE / VC Golf Invitational
Karen and Marc Jaffe
Shaking with Laughter, Tour de Fox Great Lakes
Jack Taylor’s Alexandria Toyota
Fall Field Day
Matt Keswick
Team Fox Fundraiser, Boston Fox Trot 5K
Dan Morris / Team Papa D
Spartan Sprint Race, NYC Fox Trot 5K
Thomas Strauss
TCS NYC Marathon
Team CRCF Strong
New England Parkinson’s Ride
Team ESB
Pancakes for Parkinson’s
Team Fox in the D
Detroit Gala for Parkinson’s Research
Team JPW
Tour de Fox Wine Country
Teens PD Cure
New England Parkinson’s Ride
Team VICE
TCS NYC Marathon, Berlin Marathon,
Chicago Marathon
Sonny Whelen
Racing for a Cure

100%
of Team Fox proceeds go to MJFF’s high-impact programs for a cure
In 2017, the Foundation welcomed nearly 3,000 walkers, runners, cyclists and volunteers to our Signature Series events — the Tour de Fox Cycling Series and the Fox Trot 5K Run/Walk Series. Collectively, these events raised more than $1.4 million to help accelerate a cure for Parkinson’s disease, while providing an opportunity for patients and families to forge connections.
2017 Financial Highlights

At The Michael J. Fox Foundation, we take seriously our responsibility to the Parkinson’s community. We work hard to maximize every dollar to drive science with the greatest potential to benefit patients and families. Since our inception in 2000, 88 cents of every dollar we have spent has gone directly to research programs — with more than $800 million in research funded to date.

This dedication to efficiency and accountability has always been a core value of our Foundation. And it will continue to drive us until we deliver a cure for Parkinson’s disease, and close our doors.

The 2017 financial highlights follow. Full audited financials and our most recent IRS Form 990s are available at michaeljfox.org/annualreport.

$800M+
research programs funded to date

$98M+
research programs funded in 2017

Growing Investments in PD Research
Five-year Snapshot

Where Your Money Goes
Since Inception

88%
Research Programs

9%
Fundraising

3%
Administration
## Consolidated Statements of Financial Position

**As of December 31**

<table>
<thead>
<tr>
<th>Assets</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 92,911,975</td>
<td>$ 102,142,613</td>
</tr>
<tr>
<td>Contributions receivable, net</td>
<td>23,264,963</td>
<td>20,919,938</td>
</tr>
<tr>
<td>Investments</td>
<td>13,620,255</td>
<td>11,999,431</td>
</tr>
<tr>
<td>Charitable gift annuities</td>
<td>1,232,393</td>
<td>616,319</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>4,407,633</td>
<td>1,200,352</td>
</tr>
<tr>
<td>Cash and cash equivalents – restricted</td>
<td>2,757,506</td>
<td>2,757,506</td>
</tr>
<tr>
<td>Inventory</td>
<td>24,286</td>
<td>28,256</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>6,522,373</td>
<td>1,041,945</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$ 144,741,484</strong></td>
<td><strong>$ 140,706,360</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Net Assets</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$ 4,337,439</td>
<td>$ 3,895,853</td>
</tr>
<tr>
<td>Grants payable, net</td>
<td>79,170,309</td>
<td>72,959,202</td>
</tr>
<tr>
<td>Loans payable, net</td>
<td>1,150,196</td>
<td>1,150,196</td>
</tr>
<tr>
<td>Interest payable</td>
<td>540,516</td>
<td>469,706</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>5,896,838</td>
<td>1,282,264</td>
</tr>
<tr>
<td>Annuities payable</td>
<td>617,454</td>
<td>375,036</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>2,000</td>
<td>7,000</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$ 91,714,752</strong></td>
<td><strong>$ 80,139,257</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net Assets</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$ 40,122,604</td>
<td>$ 37,677,949</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>12,904,128</td>
<td>22,889,154</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td>$ 53,026,732</td>
<td>$ 60,567,103</td>
</tr>
</tbody>
</table>

| **Total Liabilities and Net Assets** | **$ 144,741,484** | **$ 140,706,360**   |

## Consolidated Statements of Activities

**As of December 31**

<table>
<thead>
<tr>
<th></th>
<th>Temporarily Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public Support and Revenue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$ 40,191,867</td>
<td>$ 98,019,349</td>
</tr>
<tr>
<td>Special events</td>
<td>3,430,844</td>
<td>2,158,810</td>
</tr>
<tr>
<td>(Net of direct benefit to donors of $1,144,637 and $1,015,788 in 2017 and 2016, respectively)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment income gains (losses)</td>
<td>249,320</td>
<td>–</td>
</tr>
<tr>
<td>Rental income</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Miscellaneous income</td>
<td>1,023,446</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total public support and revenue before release of restrictions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>70,163,185</td>
<td>(70,163,185)</td>
</tr>
<tr>
<td><strong>Total public support and revenue</strong></td>
<td><strong>$ 115,058,662</strong></td>
<td><strong>$ (9,985,026)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>Temporarily Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>$ 98,197,740</td>
<td>–</td>
</tr>
<tr>
<td>Management and general</td>
<td>3,749,111</td>
<td>–</td>
</tr>
<tr>
<td>Fundraising</td>
<td>10,667,156</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$ 112,614,007</strong></td>
<td>–</td>
</tr>
</tbody>
</table>

| Change in net assets   | 2,444,655              | (9,985,026) | (7,540,371) | 12,428,412    |
| Net assets, beginning of year | 37,677,949            | 22,889,154 | 60,567,103 | 48,138,691 |

| **Net assets, end of year** | **$ 40,122,604** | **$ 12,904,128** | **$ 53,026,732** | **$ 60,567,103** |
2017 Financial Highlights: Canada

Canada, Michael J. Fox’s country of origin, has long been a great friend to The Michael J. Fox Foundation (MJFF). Canadian research leaders have helped to define and push forward our scientific agenda; in 2017 we awarded one of our major research prizes to a Canadian investigator (see page 13). We are grateful to our supporters to the north who contribute to our high-impact research efforts through donations and Team Fox events. MJFF officially registered as a Canadian charity in 2009.

The Michael J. Fox Foundation for Parkinson’s Research
Consolidated Statements of Activities

As of December 31

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$1,138,705</td>
<td>$2,772,894</td>
</tr>
<tr>
<td>Pledge receivable</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total Assets</td>
<td>$1,138,705</td>
<td>$2,772,894</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$7,500</td>
<td>$7,956</td>
</tr>
<tr>
<td>Research grants payable</td>
<td>396,538</td>
<td>583,015</td>
</tr>
<tr>
<td>Due to The Michael J. Fox Foundation for Parkinson’s Research (USA)</td>
<td>734,667</td>
<td>2,181,923</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>$1,138,705</td>
<td>$2,772,894</td>
</tr>
</tbody>
</table>

Statements of Operations and Changes in Net Assets

Year Ended December 31

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation donations</td>
<td>$612,230</td>
<td>$1,355,848</td>
</tr>
<tr>
<td>Other income</td>
<td>1,311</td>
<td>1,227</td>
</tr>
<tr>
<td>Total Revenue</td>
<td>$613,541</td>
<td>$1,357,075</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research grant awards</td>
<td>$599,825</td>
<td>$1,310,725</td>
</tr>
<tr>
<td>Administration and other</td>
<td>13,716</td>
<td>46,350</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>$613,541</td>
<td>$1,357,075</td>
</tr>
<tr>
<td>Excess of revenue over expenses and net assets, beginning and end of year</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
Roadmaps for Progress
The Michael J. Fox Foundation 2017 Annual Report was published in July 2018.

Founder
Michael J. Fox

Chief Executive Officer
Todd Sherer, PhD

Co-Founder & Executive Vice Chairman
Deborah W. Brooks

Deputy Chief Executive Officer
Shelley Chowdhury

Senior Vice President, Communications and Content Strategies
HollyTechwitz

Editors
Deborah Burgynski
Director, Communications
Cheryl Blowers
Associate Director, Development Communications

Creative Director
Gwen Schroeder

Senior Publications Coordinator
Emily Murphy

Writers
Anna Boyum
Lauren Carr

Design
Simplissimus
www.simplissimus.co

Photo Credits
Cover illustration and throughout: "The topography of Parkinson’s disease is complex. The Michael J. Fox Foundation exists to streamline research and therapeutic development and to find the quickest paths to a cure.

Page 2
Mark Seliger

Page 4
(Left) Elena Olivo
(Right) Filip Wolak

Pages 10 and 11
1 – Joe Shymanski
2 – Studio1923
3 – Elena Olivo
4 – Filip Wolak
5 – Courtesy of NASA
6 – Getty Images / Nicholas Hunt
7 – Courtesy of Verily Life Sciences
8 – Getty Images / Jamey McCarthy
9 – Flip Wolak
10 – Courtesy of “CBS Sunday Morning”
11 – Andrew Kist

Page 13
Andrew Kist

Page 17, 21, 46–47
Courtesy of MJFF supporters and their families and friends

Page 29
Courtesy of Dignitas

Page 35
Joe Shymanski

Page 47
3 – Elena Olivo
4 – Filip Wolak

Credits
Boards and Councils

Board of Directors

Chairman
Jeff Kaufer

Vice Chairman
Skip Inouye

Holly S. Andersen, MD
Glenn Batchelder
Mark Booth
Jon Broolis
Barry J. Cohen
Andrew Crestfjeld
John S. Daly
Donny Deutsch
David Einhorn
Karen Finerman
Lee Fixel
Michael J. Fox
Akbar Gbajabiamila
Willie Geist
David Glickman
David Golub
Mark L. Hart III
Anne M. Holloway
Edward Kalikow
Amar Kuchinad
Marc S. Lipschultz
Ofer Nemirovsky
Andy O’Brien
Douglas I. Ostrover
Tracy Pollan
Ronnie Prince
Omar Abdul-Hakim
Shakeel Alem
Loren Berger
Felix Brandoni
Susan Bielat
Zachary Brotz
Alexandra Cherubini
Dev Chopra
Taryn Fixel
Michael Kiplan
Juliana Hey
Justin Kapone
Pamela Mehl
Dan Morris
Rafi Rosen
Scott Schein
Bill Shepherd
Ryan Squillante
Meredith Tutunow

Leadership Council

Chairman
Richard Fitzgerald

Vice Chairman
Daisy Prince

Omar Abdul Hakim
Shakeel Alem
Loren Berger
Felix Brandoni
Susan Bielat
Zachary Brotz
Alexandra Cherubini
Dev Chopra
Taryn Fixel
Michael Kiplan
Juliana Hey
Justin Kapone
Pamela Mehl
Dan Morris
Rafi Rosen
Scott Schein
Bill Shepherd
Ryan Squillante
Meredith Tutunow

Founders’ Council

Lorraine and Mohammad Ali
Steven A. Cohen
Albert B. Dickman
John Griffin
Andrew S. Grove
Kate Hood
Jeffrey Katzenberg
Morton M. Kondracke
Evelyn A. Levy
Nancy McNiff
Donna Shalala, PhD

Patient Council

Co-Chairs
Soania Mathur, MD
Bret Parker

Carolyn Schenker
Curtis Schenker
Richard J. Schnall
Woody Shaiken
Anne-Cecilie Engell Speyer
George Stephanopoulos
Bonnie Strauss
Rick Tyler
Fred G. Weiss
Sammy Weeken
Peter Zaffino

Executive Scientific Advisory Board
Becky Baker, MD, PhD
Alice Chen-Potkin, MD
Ted Dawson, MD, PhD
John D'Amato, PhD
Steven Finkbeiner, MD, PhD
Tatiana Foroud, PhD
Women's Brain
Karl Kieburtz, MD, MPH
Ken Marder, MD
Constance Morris, MD, PhD
Kapriya M. Merchant, PhD
Michael Schwartzach, MD, PhD

Public Policy Council
Melissa Bleichman
David Charles, MD
Phil Cox
Quentin Dastugue
Tom Davidson
Douglas L. DuMond
Col. Karl E. Friedl, PhD, Ret.
David Higgins, PhD
Julius W. Hobsbom Jr.
Matt Kaweck
Rod Lenson
Jessica Lawrence-Vaca
Daniel Lewis, JD
Monnie Lindsay, JD
Jeff Shrum
Anne J. Udall, PhD

The Michael J. Fox Foundation 2017 Annual Report was published in July 2018.
“The latest research is the latest hope.”

—Michael J. Fox